Business
Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris
Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansionMore than 50 million people affected by acne in US each year, with market valued at $5.7 billion in 2024 WOBURN, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of phot
About this update from Biofrontera Inc.
[{"type":"image","alt":"Biofrontera Inc.","displaySize":"","headline":null,"caption":"Biofrontera Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/f8bea715aa1dcdf4aff565eecd02fa4b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bVH36b1WxYUx1e199mXo7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f8bea715aa1dcdf4aff565eecd02fa4b","width":300,"height":150}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansion","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"More than 50 million people affected by acne in US each year, with market valued at $5.7 billion in 2024","length":104,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":295,"olType":false},{"type":"text","content":"WOBURN, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced that the final patient in its Phase 2b clinical trial evaluating Ameluz® (aminolevulinic acid hydrochloride) for the treatment of moderate to severe acne vulgaris (AV) completed participation on August 22, 2025.","length":455,"tagName":"p"},{"type":"text","content":"Acne vulgaris is a common skin condition characterized by inflammatory and non-inflammatory lesions that frequently lead to permanent scarring. Beyond the physical burden, AV often has a significant psychological impact, including reduced self-esteem and depression.","length":266,"tagName":"p"},{"type":"text","content":"Current U.S. guidelines recommend a range of treatment options for AV, including topical agents, systemic antibiotics, hormonal therapies, isotretinoin and physical treatments. However, many of these options carry limitations such as serious side effects, teratogenic risks, the need for continuous daily dosing, or—particularly with antibiotics—growing concerns about resistance. As a result, there remains a critical unmet need for...